knowledge -WSS

knowledge

author：entertainment 2025-09-30 00:37:39 - browse：48

From left: Daphne Koller, CEO of Insitro, Vijay Pande of Andreessen Horowitz and scientist Derek Lowe speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.

To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens. All you need to get to a cure — as they say in infomercials — is act now!

“I am very worried about the hype,” said Daphne Koller, chief executive of the machine learning drug discovery company Insitro, said during STAT’s Breakthrough West Summit in San Francisco last week. “People think (the breakthrough) is going to happen tomorrow.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Hospital chaplains balance Covid safety with patients’ spiritual needs

WSS

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Ransomware attacks on hospitals: Study outlines patient impact

Merck to acquire Harpoon Therapeutics for $680 million

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Hepatitis C has a cure — but many Americans still lack access to it

Profiling embryos to choose those with higher IQs is almost a reality

Hepatitis C has a cure — but many Americans still lack access to it

Medicare Advantage coverage denials need scrutiny, senators say

Continuity nursing helped my family in our darkest PICU moments

Study suggests new cause of Down syndrome: cells linked to aging

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Wikipedia

CRISPR pioneers react to Casgevy, first gene

Does good food count as health care? Study aims to find out

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Gene therapy denied for Afghan refugee whose father aided U.S.

Does Paxlovid work in people vaccinated against Covid

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

hotspot

explore

Wikipedia

focus